NYSE - Delayed Quote USD

Novartis AG (NVS)

Compare

97.77

-0.59

(-0.60%)

At close: December 16 at 4:00:02 PM EST

98.23

+0.46

(+0.47%)

After hours: December 16 at 5:53:19 PM EST

The Zacks Analyst Blog Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology

Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology are included in this Analyst Blog.

Zacks 3 days ago

NVS
-0.60%
MA

IDT
Top Stock Reports for Mastercard, Procter & Gamble & Novartis

Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), The Procter & Gamble Company (PG) and Novartis AG (NVS), as well as two micro-cap stocks, IDT Corporation (IDT) and GSI Technology, Inc. (GSIT).

Zacks 4 days ago

NVS
-0.60%
MA

PG
Monte Rosa Closes Global License Agreement With Novartis

Monte Rosa Therapeutics (GLUE) said Wednesday it has closed its development and commercialization li

PREMIUM
MT Newswires 5 days ago

NVS
-0.60%
GLUE
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between anatomical stages1Real-world 5-year distant recurrence data in high-risk patients with HR+/HER2- early breast cancer (EBC), regardless of nodal status, highlights importance of adding a CDK4/6 inhibitor to endocrine therapy for all eligible patients2Late-breaking Kisqali data presentations at SABCS follow r

GlobeNewswire 6 days ago

NVS
-0.60%
NVSEF
Novartis Announces Positive Results From Late-Stage Study on Fabhalta

NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies.

Zacks 7 days ago

NVS
-0.60%
PFE
Novartis reports topline outcomes from Phase IIIB PNH trial of Fabhalta

The open-label, single-arm trial involved 52 subjects.

Clinical Trials Arena 7 days ago

NVS
-0.60%
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key secondary endpoints1 Scemblix showed a clinically relevant 15.1% higher MMR rate vs. second generation (2G) TKIs (72.0% vs. 56.9%)1 96-week data extend favorable safety and tolerability profile for Scemblix vs. imatinib and 2G TKIs, with fewer grade ≥3 AEs and less than half the discontinuation rate

GlobeNewswire 8 days ago

NVS
-0.60%
NVSEF
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were switched from anti-C5 therapies (Hb ≥10g/dL following treatment with eculizumab or ravulizumab)1,2PNH is a rare, chronic and serious complement-mediated blood disorder, characterized by hemolysis, anemia, thrombosis and other symptoms, and patients are often treated with anti-C5 therapies3-5Findings fr

GlobeNewswire 10 days ago

NVS
-0.60%
NVSEF
Why Novartis (NVS) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 12 days ago

NVS
-0.60%
PTC Therapeutics price target raised to $71 from $47 at UBS

UBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday announced a global licensing and collaboration agreement with Novartis (NVS) for its Huntington’s Disease program, PTC518, under which PTC will receive $1B at closing and is eligible for up to $1.9B in development, regulatory and sales milestones, the analyst tells investors in a research note. PTC is a high conviction call into 2025, where UBS sees PTC a

TipRanks 12 days ago

NVS
-0.60%
NVSEF

PTCT
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.

Zacks 13 days ago

NVS
-0.60%
PTCT

OLMA
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.

Zacks 13 days ago

PTCT

NVS
-0.60%
SPRO
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 13 days ago

NVS
-0.60%
Novartis and Olema expand alliance with $250m to boost breast cancer trials

Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.

Pharmaceutical Technology 13 days ago

NVS
-0.60%
OLMA
Novartis and PTC Therapeutics link to develop Huntington’s therapy

PTC Therapeutics is set to obtain an upfront payment of $1bn.

Pharmaceutical Technology 13 days ago

NVS
-0.60%
PTCT
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.

Investor's Business Daily 14 days ago

NVS
-0.60%
NVSEF

PTCT
Sector Update: Health Care Stocks Slipping Late Afternoon

Health care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health

PREMIUM
MT Newswires 14 days ago

PTCT

SNTI

NVS
-0.60%
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis AG (NYSE:NVS) for its PTC518 Huntington’s disease program, which includes related molecules. Under the agreement, PTC will receive an upfront payment of $1.0 billion, up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales. Also Read: FDA Grants Conditional Approval For PTC Therapeut

Benzinga 14 days ago

PTCT

NVS
-0.60%
PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis.

Investopedia 14 days ago

PTCT

NVS
-0.60%
Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%

A groundbreaking drug, a massive deal, and a stock rally--this could reshape neurodegenerative disease treatments.

GuruFocus.com 14 days ago

NVS
-0.60%
PTCT

Performance Overview

Return	NVS	MSCI WORLD
YTD	+0.53%	+20.80%
1-Year	+4.21%	+22.46%
3-Year	+35.37%	+20.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novartis AG (NVS)

The Zacks Analyst Blog Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology

Top Stock Reports for Mastercard, Procter & Gamble & Novartis

Monte Rosa Closes Global License Agreement With Novartis

Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

Novartis Announces Positive Results From Late-Stage Study on Fabhalta

Novartis reports topline outcomes from Phase IIIB PNH trial of Fabhalta

Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

Why Novartis (NVS) is a Top Growth Stock for the Long-Term

PTC Therapeutics price target raised to $71 from $47 at UBS

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Novartis and Olema expand alliance with $250m to boost breast cancer trials

Novartis and PTC Therapeutics link to develop Huntington’s therapy

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone

Sector Update: Health Care Stocks Slipping Late Afternoon

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%

Performance Overview